Account

Search results for: orphan drugs

Orphan drugs not included in reference price order

The Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...

Read more
Orphan drugs undergo early benefit assessment

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...

Read more
Orphan drugs market access

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo a r...

Read more
Orphan Drugs and Diseases: 101

This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...

Read more
Access to orphan drugs in the EU

Differences in market access and reimbursement processes are an important factor in determining the ...

Read more
Patient access to high-cost orphan drugs

Orphan drugs have important societal value as they improve patient quality of life and address unmet...

Read more
World Orphan Drug Congress Europe 2024

We're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...

Read more
World Orphan Drug Congress Europe 2023 REPORT

We summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...

Read more
Orphan Medicine Market Access in Europe

Webinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...

Read more
ISPOR 2022: Changing landscape of Orphan Drug Reim...

We compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch